Business Context and Reporting Period
This Form 8-K was filed by PharmaCyte Biotech, Inc. on July 21, 2022. The report serves as a current update regarding the commencement of the pilot phase of the Company's two-phase pig study. The Company is incorporated in Nevada and its common stock trades on The Nasdaq Stock Market LLC under the symbol PMCB.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on operational milestones rather than financial performance data.
Material Changes
- Operational Milestone: The Company announced the start of the pilot phase of its two-phase pig study.
- Corporate Governance: The Company is soliciting proxies for its 2022 Annual Meeting of Stockholders. A definitive proxy statement and WHITE proxy card are expected to be filed with the SEC.
Outlook, Risks, and Management Commentary
Management directs investors to the press release furnished as Exhibit 99.1 for details on the pig study. Regarding the upcoming Annual Meeting, the Company emphasizes that stockholders should carefully read the definitive proxy statement and accompanying materials, which will contain information on the direct and indirect interests of directors and executive officers. The filing notes that updated information on security holdings will be available in Forms 3, 4, and 5, as well as the Annual Report on Form 10-K for the year ended April 30, 2022.
Key Facts for Investor Verification
- Verify the specific details and objectives of the two-phase pig study pilot phase in the press release (Exhibit 99.1).
- Review the definitive proxy statement for the 2022 Annual Meeting once filed to assess director and officer security holdings.
- Check the upcoming Form 10-K for the fiscal year ended April 30, 2022, for comprehensive financial data not included in this 8-K.
- Monitor Forms 3, 4, and 5 for subsequent changes in insider holdings.